key: cord-0730311-ev59yr9f authors: Lei, Haike; Yang, Yue; Zhou, Wei; Zhang, Mengyang; Shen, Yang; Tao, Dan; Wang, Lulu; Lei, Qianqian; Wang, Ying; Wu, Yongzhong title: Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis date: 2021-05-05 journal: Lung Cancer DOI: 10.1016/j.lungcan.2021.05.002 sha: d4b1d0d068661eefc466faa0e3a59ab249153c42 doc_id: 730311 cord_uid: ev59yr9f OBJECTIVE: Given that the coronavirus disease 2019 (COVID-19) mainly spreads through the respiratory system and is associated with severe pulmonary complications, lung cancer patients may have worse outcomes than those with other tumors. There is no confirmed evidence about the mortality comparison between COVID-19 patients with lung cancer and other tumors. We performed a systematic review and pooled analysis to provide precise estimates of the mortality rate of COVID-19 patients with lung cancer and other tumors. MATERIALS AND METHODS: Our study systemically included and reviewed 13 studies on the characteristics of COVID-19 patients with lung cancer published up to November 1, 2020. The primary endpoint was all-cause mortality. We also compared the all-cause mortality rates in China and other regions as a secondary endpoint. The mortality rate was assessed with a fixed-effects model, which was used to derive the pooled mortality and 95% confidence interval (CI). RESULTS: Thirteen studies from different countries, involving 1,229 patients with both COVID-19 and cancer, were selected for the pooled analysis. A total of 343 deaths were recorded in this population: 86 for lung cancers and 257 for other tumors. The mortality rate varies from 18% to 60% for patients with lung cancer and COVID-19 and 10% to 41% for other tumor patients with COVID-19. The overall meta-analysis did not show a significant mortality difference for the lung cancer and other tumor subgroups (OR = 1.47, 95%CI = 0.98-2.20, p = 0.06, I(2) = 23%). Nevertheless, in regions other than China, the pooled mortality of lung cancer patients with COVID-19 was 42%, which was significantly higher than that of other tumors (24%) (OR = 2.73, 95% CI = 1.54-4.86, p = 0.0006, I(2) = 16%). CONCLUSION: Appropriate and aggressive preventive measures should be implemented to reduce the risk of COVID-19 in patients with cancer and optimally manage those who contract the infection. The COVID-19 pandemic has had a significant impact on patients with cancer. Patients with cancer are susceptible to COVID-19 because immunosuppressive treatments can weaken the immune system, and COVID-19 complications, such as acute respiratory distress syndrome and mechanical ventilation, may lead to worse survival. Second, a sharp reduction in cancer screening and the postponement of ongoing or planned therapy during the pandemic's initial months may have also resulted in excess deaths from cancer. Additionally, cancers occur often in the older adult population, and cancer patients commonly have other comorbidities, which may increase the risk of poor outcomes. Therefore, it has been presumed that cancer is a risk factor for severe COVID-19. Among the types of cancer, lung cancer has been the most studied. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contaminates the respiratory system and causes respiratory complications of the lungs, which worsens the prognosis of lung cancer patients. Ziegle et al. demonstrated that angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2) on the alveolar epithelial cells are the receptors for SARS-CoV-2 to invade the human body, and the abnormal respiratory epithelium is likely to be more prone to rapid virus entry into the lungs (1). The most controversial point was determining whether lung cancer patients have a higher risk of contagiousness or lung cancer was more severe than other cancer types when complicated by COVID-19. In an observational study conducted in China, most COVID-19 cases had lung cancer (19.6%) compared with gastrointestinal (18.7%) and genitourinary (18.7%) cancers (2) . Other results from a multi-center study in the early days of the coronavirus outbreak indicated that J o u r n a l P r e -p r o o f patients with lung cancer or lung metastasis showed a considerably higher risk of death (OR, 2.34; 95% confidence interval [CI], 1.15-4.77); P = 0.03), higher ICU admission rates (OR, 2.84; 95% CI [1.59-5.08]; P < 0.01), and higher risks of other critical events than patients with other cancers without lung metastasis (3) . Another systemic review reported that patients with hematological malignancies (OR, 2.39; 95% CI, 1.17-4.87); P = 0.02) and lung cancer (OR, 1.83; 95% CI, (1.00-3.37); P = 0.05] who were infected by COVID-19 had the highest mortality (4); in contrast, another study by Liang reported that lung patients with lung cancer did not have a higher probability of severe events (5). In the above studies, the sample sizes varied; the samples included 7-102 patients with lung cancer. The enrollment time spanned various stages of the epidemic, which resulted in heterogeneous and inconsistent opinions. Therefore, we conducted this systematic review to assess the mortality of lung cancer patients infected by COVID-19. All systematic review and meta-analysis procedures were conducted according to the Systematic Reviews and Meta-Analyses (PRISMA) Statement relevant to healthcare (6). We followed an established protocol registered in the International Prospective Register of Systematic Reviews (PROSPERO), and the record is available at https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020222523(7). A systematic literature search and review of studies published in PubMed, Google Scholar, Web of Science, and MedRxiv between February 1 and October 31, 2020, were performed by two investigators (Yue Y. and Haike L.). To amply search the literature, we conducted the literature searches using a combination of medical subject headings (MeSH) and free terms, such as "COVID-19" and "lung cancer." For COVID-19, the search items were as follows: "novel coronavirus" OR "SARS-CoV-2" OR "COVID-19." For lung cancer, the search term was "cancer" OR "carcinoma" OR "tumor" OR "NSCLC" OR "lung cancer." We used "AND" to combine the items of the two keywords. The selected data were screened independently by two investigators (Yue Y. and Haike L.). During the preliminary screening, studies that were irrelevant to the study, based on their titles and abstracts, were excluded. The full text was required for further screening. All included studies need to be checked for duplicate medical records from the same or overlapping cohort of patients. Subsequently, all procedures were cross-checked by the two investigators. The inclusion criteria were as follows: (i) studies enrolling patients with COVID-19 and lung cancer, and COVID-19 should have been diagnosed clinically or based on laboratory tests; the diagnosis of lung cancer or other tumors should have had no restriction of pathological type and J o u r n a l P r e -p r o o f stage, primary or secondary; (ii) studies reporting mortality rate in patients with lung cancer and COVID-19; (iii) any kind of study (including retrospective studies, randomized controlled trials, prospective cohort studies, and case series); (iv) studies published in the English language. The exclusion criteria were as follows: (i) publication types including conference abstracts, case reports, letters, comments, non-human studies, and studies with incomplete data; (ii) studies published in languages other than those mentioned above. Two investigators independently extracted the data. The extracted data consisted of the first author's name, type of publication (i.e., peer-reviewed, preprint, or conference proceedings), population country, single-center or multi-center study type (retrospective or prospective, RCT, case series, cohort control), diagnostic methods of COVID-19, reported number of patients with lung cancer and COVID-19, the number of deaths among the study population, and other characteristics of patients. Two reviewers (Yang S. and Mengyang Z.) independently assessed the quality of the included studies. The Newcastle-Ottawa Scale (NOS) and NICE guideline (NG45) were used to determine the quality of case-control studies and case series, respectively. The primary outcome was all-cause mortality in patients with lung cancer and COVID-19 infection, and the secondary endpoint was all-cause mortality in China and other regions. Odds ratios (ORs) were calculated. A 95% confidence interval (CI) was reported for the outcomes. The value of I 2 and the result of the chi-squared test were used to assess statistical heterogeneity. High heterogeneity was considered when I 2 > 50%. A fixed-effects model was used, and p < 0.05 denoted statistical significance. The meta-analysis was performed using RevMan 5.3 (The Cochrane Collaboration, London, United Kingdom). A flowchart of the literature search is presented in Figure 1 Ten studies involving 1,087 patients (138, lung cancer group; 949, other tumor group) have reported mortality comparisons (Figure 2 ). There were 44 deaths and 257 deaths in the lung cancer and other tumor groups, respectively. The mortality rate in the lung cancer group was 32%, which was higher than the 27% for the other tumors group (OR=1.47, 95%CI=0.98-2.20). Heterogeneity testing revealed minimal heterogeneity, with I 2 = 23% (p = 0.24). Therefore, we used the fixed-effects model. The overall mortality was not significantly different (p=0.06). Publication bias was evaluated using a funnel plot (Figure 5a) , which showed no substantial evidence of asymmetry. Heterogeneity testing in these two subgroups revealed minimal heterogeneity, with I 2 = 16% ( Figure 3 ) and I 2 = 16% (Figure 4 ). We used a fixed-effects model. Mortality in the Chinese subgroup showed no significant differences (p=0.72), significant differences were observed in the other regions (p=0.0006); the mortality of the lung cancer group was 42%, which was higher than that for other tumors (24 %). Publication bias was evaluated using a funnel plot (Figure 5b and 5c), and it showed no significant evidence of asymmetry. There are some limitations to our study. Since most of the studies included in our analysis reported the all-cause mortality rate other than the case fatality rate, the evidence for the cause of death, including COVID-19, cancer, or other comorbidities, was insufficient. More prospective and well-organized studies should be conducted to investigate the main cause of death in these patients and evaluate the impact of different etiologies and clinical factors on prognosis, and more balanced strategies may be adopted. Moreover, although we planned to take age, sex, cancer stage, and comorbidities into consideration, only a few included studies provided these detailed data for a pooled analysis. As is customary with the included studies, our findings are relatively intuitive; nonetheless, having objective data to confirm our suspicions about the mortality of lung cancer patients with COVID-19 should help in the development of evidence-based recommendations for the deployment of limited resources within healthcare environments. Which cancer type has the highest risk of COVID-19 infection? Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak A systematic review and meta-analysis of cancer patients affected by a novel coronavirus Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias The nuts and bolts of PROSPERO: an international prospective register of systematic reviews SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study COVID-19 in patients with lung cancer Covid-19 and lung cancer: A greater fatality rate? Lung Cancer Outcomes of COVID-19 in Patients With Lung Cancer Treated in a Tertiary Hospital in Madrid Cancer inpatients with COVID-19: A report from the Brazilian National Cancer Institute SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA oncology Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer discovery Characteristics and outcome of SARS-CoV-2 infection in cancer patients Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy) Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: a multi-centre North London experience